Telephone Counseling for Tobacco Cessation
4. desember 2018 oppdatert av: Kaiser Permanente
Evaluation of Brief, Structured, Telephone Counseling for Tobacco Cessation as Part of a Cardiovascular Risk Reduction Service
The purpose of this study is to determine whether giving more structured information to patients over the phone about quitting tobacco helps to increase the chance that they will try to quit. The results of this study will help provide direction in developing a more standard way of helping patients to quit.
Study Hypothesis:
Brief, structured, telephone tobacco cessation counseling delivered by clinical pharmacy specialists will significantly increase the percentage of self-reported tobacco cessation attempts compared to usual care among patients enrolled in a cardiovascular risk reduction program.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
While physician-delivered care may have the greatest impact on tobacco abstinence rates, recent data indicate that other health care providers such as nurses and pharmacists improve tobacco abstinence rates more than self-help and/or no intervention.5
Thus, pharmacists continue to expand their clinical practice areas to include smoking cessation interventions.
A meta-analysis of studies involving pharmacist-delivered smoking cessation services found quit rates at 6 to12 months follow-up ranged from 14% to16%.6
The results of this meta-analysis demonstrate that pharmacists can successfully deliver tobacco-cessation interventions and the evidence strongly suggests they are effective in helping increase tobacco cessation rates.
Proactive telephone counseling can be more effective at increasing tobacco abstinence rates than self-help or no intervention.5
Telephone counseling is an effective system to help increase tobacco abstinence rates for a variety of reasons.
From the tobacco user's standpoint, there are no transportation inconveniences and fewer scheduling conflicts.
In addition, receiving counseling in the privacy of one's own home provides treatment access to individuals who are less willing to seek out counseling.
At Kaiser Permanente Colorado (KPCO), members with a history of CVD are enrolled in the Clinical Pharmacy Cardiac Risk Service (CPCRS).
The CPCRS is a clinical pharmacy specialist-managed, physician-directed program which provides secondary prevention care to over 14,000 patients.
Clinical care includes evaluating and treatment of major cardiovascular risk factors, including tobacco use, for members.
Currently, CPCRS has no standard of care with regard to addressing tobacco use.
Clinical pharmacy specialists working in CPCRS deliver tobacco cessation advice at their own discretion, through various methods.
The purpose of this pilot study is to determine whether brief, structured, telephone tobacco cessation counseling delivered by a clinical pharmacy specialist increases the number of smoking cessation attempts compared to usual care.
Studietype
Intervensjonell
Registrering (Faktiske)
192
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80011
- Clinical Pharmacy Specialist, Clinical Pharmacy Cardiac Risk Service - Kaiser Permanente of Colorado
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
Patients who meet the following criteria will be eligible for the study:
- Enrolled in CPCRS at the time of counseling (12/11-02/12),
- Current tobacco user as noted in KP HealthConnect as of the date of the routine CPCRS evaluation and counseling. For study purposes, tobacco use includes any use of cigarettes, pipe, cigars, snuff, and chew.
- Continuous KPCO Denver/Boulder membership during study time period
Exclusion Criteria:
- Patients who meet any of the following criteria will not be enrolled in the study:
- <18 years of age,
- Non-English speakers,
- Deceased at time of survey, and/or
- Unable to provide consent
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: BST counseling group
The patients in the Brief, structured, telephone tobacco cessation, BST, counseling group, will receive tobacco cessation counseling, intervention, by a trained CPCRS pharmacist as part of their routine CPCRS care.
The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C).
These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting.
A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources.
|
The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care.
The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C).
These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting.
A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources ("Ready to quit" patient handout)
|
|
Placebo komparator: Usual care group
Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices.
These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications.
Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
|
Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices.
These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications.
Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The Percentage of Self-reported Tobacco Cessation Attempts Between Groups
Tidsramme: 3 months
|
The proportion of patients in each group who report a tobacco cessation attempt during the follow-up telephone survey conducted three months following pharmacist contact
|
3 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The Proportion of Patients in Each Group Who Participate in the Colorado Quitline (COQL) Within Three Months of Pharmacist Contact
Tidsramme: 3 months
|
Information on COQL participation was obtained from a prevention department within KPCO that tracks these data.
Report was provided to capture who from study had participated in the COQL within 3 months of pharmacist contact.
|
3 months
|
|
The Proportion of Patients Who Attend Any KPCO Tobacco Cessation Program(s)or Webinar(s) Within Three Months Following Contact.
Tidsramme: 3 months
|
The proportion of patients who attend any KPCO tobacco cessation program(s)or webinar(s) within three months following contact.
Classes include Stop Smoking the Basics and Freedom from Cigarettes.
Webinars include Break Free and Freedom from Tobacco
|
3 months
|
|
The Proportion of Patients in Each Group Who Purchase Tobacco Cessation Medication Aids From KPCO Pharmacies Within Three Months Following Pharmacist Contact.
Tidsramme: 3 months
|
The proportion of patients in each group who purchase tobacco cessation medication aids from KPCO pharmacies within three months following pharmacist contact.
Medications include nicotine replacement therapy, bupropion, and varenicline
|
3 months
|
|
The Proportion of Patients in Each Group Who Report Tobacco Abstinence During at the Three Months Follow-up Telephone Survey
Tidsramme: 3 months
|
The proportion of patients in each group who report tobacco abstinence during the follow-up telephone survey conducted three months following pharmacist contact
|
3 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Alicia Cymbala, PharmD, BCPS, Kaiser Permanente
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. november 2011
Primær fullføring (Faktiske)
1. desember 2014
Studiet fullført (Faktiske)
1. januar 2015
Datoer for studieregistrering
Først innsendt
8. desember 2011
Først innsendt som oppfylte QC-kriteriene
8. desember 2011
Først lagt ut (Anslag)
9. desember 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. mars 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
4. desember 2018
Sist bekreftet
1. desember 2018
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CO-11-1660
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Nei
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .